Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JXW7 | ISIN: US88322Q1085 | Ticker-Symbol: NKB2
Tradegate
21.05.24
17:33 Uhr
15,476 Euro
-0,886
-5,42 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TG THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TG THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,20016,60022.05.
16,19416,52822.05.

Aktuelle News zur TG THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Peering Into TG Therapeutics' Recent Short Interest8
06.05.TG THERAPEUTICS, INC. - 10-Q, Quarterly Report1
03.05.Earnings call: TG Therapeutics sees strong Q1 growth with Briumvi4
03.05.Why TG Therapeutics Stock Was Rocketing Higher This Week2
01.05.TG Therapeutics stock just rallied 30%: what happened?15
01.05.TG Therapeutics jumps as Q1 Briumvi sales top guidance4
01.05.TG Therapeutics Inc. Q1 Loss decreases, but misses estimates7
01.05.Pre-market Movers: IM Cannabis, CVRx, TG Therapeutics, Root, Inc., Plutonian Acquisition292WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86. TG...
► Artikel lesen
01.05.TG Therapeutics GAAP EPS of -$0.07 misses by $0.03, revenue of $63.47M beats by $8.86M3
01.05.TG THERAPEUTICS, INC. - 8-K, Current Report3
30.04.TG Therapeutics, Inc.: TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update6
18.04.TG Therapeutics wins VA contract for Briumvi14
18.04.TG Therapeutics, Inc.: TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting87NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy)...
► Artikel lesen
18.04.TG Therapeutics, Inc.: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis1
15.04.TG Therapeutics, Inc.: TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting7
08.03.TG Therapeutics, Inc.: TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting227NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating...
► Artikel lesen
01.03.Earnings call: TG Therapeutics reports robust BRIUMVI sales in 202317
29.02.TG THERAPEUTICS, INC. - 10-K, Annual Report2
29.02.TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript7
28.02.TG Therapeutics jumps after Q4 rev tops estimates18
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8